Small Molecules

03 Oct 2017 Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting
03 Oct 2017 Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial
03 Oct 2017 FDA Accepts Supplemental New Drug Application (sNDA) filing for AVYCAZ® (ceftazidime and avibactam)
03 Oct 2017 Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program
03 Oct 2017 Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
03 Oct 2017 Takeda Announces Positive Results from its Phase 3 Confirmatory Clinical Trial in Japan Evaluating the Efficacy and Safety of GnRH Receptor Antagonist Relugolix in Uterine Fibroids
30 Sep 2017 Radius Health Initiates Phase 1 Clinical Trial of RAD140 for the Treatment of Hormone Receptor Positive Breast Cancer
30 Sep 2017 FDA approves new treatment for certain advanced or metastatic breast cancers
30 Sep 2017 INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA
30 Sep 2017 Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
30 Sep 2017 Merck Discontinues MK-3682B and MK-3682C Development Programs
28 Sep 2017 Eidos Therapeutics Initiates First Clinical Study for AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis as Chief Business Officer
28 Sep 2017 Tricida Initiates Phase 3 Study of TRC101 for the Treatment of Metabolic Acidosis Associated With Chronic Kidney Disease
28 Sep 2017 Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
28 Sep 2017 Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc
27 Sep 2017 Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML
27 Sep 2017 Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas
27 Sep 2017 Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211
27 Sep 2017 Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study
27 Sep 2017 Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease
26 Sep 2017 European Commission Approves Symtuza® for the Treatment of HIV-1 In Adults and Adolescents in Europe
26 Sep 2017 Medivir Announces Positive Topline Results from Phase IIa Osteoarthritis Study, Showing Disease-modifying Benefit of MIV-711 on Joint Structure
26 Sep 2017 Gelesis100 Achieves Significant Weight Loss with Excellent Safety Profile in Pivotal Study
25 Sep 2017 Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1
25 Sep 2017 Shionogi Announces Results for Lusutrombopag (S-888711) Phase 3 Study (L-PLUS2) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing